SWTX - What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? | Benzinga
SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with NF1-associated plexiform neurofibromas (NF1-PN).
The primary endpoint was confirmed objective response rate (ORR), defined as ≥ 20% reduction in target tumor volume.
As of the data cutoff date of September 20, 2023, 52% (29/56) of pediatric patients and 41% (24/58) of adult patients had objective ...